EP1140036A2 - Novel formulations comprising lipid-regulating agents - Google Patents
Novel formulations comprising lipid-regulating agentsInfo
- Publication number
- EP1140036A2 EP1140036A2 EP99967317A EP99967317A EP1140036A2 EP 1140036 A2 EP1140036 A2 EP 1140036A2 EP 99967317 A EP99967317 A EP 99967317A EP 99967317 A EP99967317 A EP 99967317A EP 1140036 A2 EP1140036 A2 EP 1140036A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- lipid
- propylene glycol
- regulating agent
- fenofibrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Definitions
- the present invention relates to novel formulations for oral administration comprising lipid-regulating agents.
- 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1 -methylethylester, also known as fenofibrate, is representative of a broad class of compounds having pharmaceutical utility as lipid regulating agents. More specifically, this compound is part of a lipid-regulating agent class of compounds commonly known as fibrates, and is disclosed in U.S. Patent No. 4,058,552.
- Fenofibrate has been prepared in several different formulations, c.f, U.S. Patent No. 4,800,079 and U.S. Patent No. 4,895,726.
- U.S. Patent No. 4,895,726 discloses a co- micronized formulation of fenofibrate and a solid surfactant.
- U.S. Patent No. 4,961,890 discloses a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles included within pores of an inert matrix.
- the formulation is prepared by a process involving the sequential steps of dampening said inert core with a solution based on said binder, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying, before said solution based on said binder dissolves said fenofibrate microparticles, and repeating said three steps in sequence until said intermediate layer is formed.
- European Patent Application No. EP0793958A2 discloses a process for producing a fenofibrate solid dosage form utilizing fenofibrate, a surface active agent and polyvinyl pyrrolidone in which the fenofibrate particles are mixed with a polyvinyl pyrrolidone solution. The thus obtained mixture is granulated with an aqueous solution of one or more surface active agents, and the granulate thus produced is dried.
- PCT Publication No. WO 82/01649 discloses a fenofibrate formulation having granules that are comprised of a neutral core that is a mixture of saccharose and starch. The neutral core is covered with a first layer of fenofibrate, admixed with an excipient and with a second microporous outer layer of an edible polymer.
- U.S. Patent No. 5,645,856 describes the use of a carrier for hydrophobic drugs, including fenofibrate, and pharmaceutical compositions based thereon.
- the carrier comprises a digestible oil and a pharmaceutically-acceptable surfactant component for dispersing the oil in vivo upon administration of the carrier, which comprises a hydrophilic surfactant, said surfactant component being such as not to substantially inhibit the in vivo lipolysis of the digestible oil.
- Gemfibrozil is another member of the fibrate class of lipid-regulating agents.
- U.S. Patent No. 4,927,639 discloses a disintegratable formulation of gemfibrozil providing both immediate and sustained release, comprising a tablet compressed from a mixture of a first and second granulation, and a disintegration excipient operable to effect partial or complete disintegration in the stomach.
- the first granulation comprises finely divided particles of pure gemfibrozil granulated with at least one cellulose derivative
- the second granulation comprises finely divided particles of pure gemfibrozil granulated with a pharmaceuitcally-acceptable water soluble or insoluble polymer which are then uniformly coated with a pharmaceuitcally-acceptable (meth)acylate copolymer prior to admixture with the first granulation.
- the first and second granulations are present in the final composition in a ratio of from about 10:1 to about 1 :10.
- U.S. Patent 4,925,676 discloses a disintegratable gemfibrozil tablet providing both immediate and enteric release, which is compressed from a mixture of a first granulation of gemfibrozil with at least one acid-disintegratable binder, and a second granulation formed from the first granulation, but regranulated or coated with an alkali-disintegratable formulation of at least one substantially alkali-soluble and substantially acid-insoluble polymer.
- statins Another class of lipid-regulating agents are commonly known as statins, of which pravastatin and atorvastatin are members.
- U.S. Patents 5,030,447 and 5,180,589 describe stable pharmaceutical compositions, which when dispersed in water have a pH of at least 9, and include a medicament which is sensitive to a low pH environment, such as prevastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.
- prevastatin one or more fillers such as lactose and/or microcrystalline cellulose
- binders such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder)
- disintegrating agents
- the present invention is directed to formulations for oral administration comprising a lipid-regulating agent, further comprising at least one propylene glycol fatty acid ester as the primary solvent medium for the lipid-regulating agent.
- a lipid-regulating agent further comprising at least one propylene glycol fatty acid ester as the primary solvent medium for the lipid-regulating agent.
- One or more emulsifiers may optionally be added to the formulation.
- the formulation may be administered directly, diluted into an appropriate vehicle for administration, encapsulated into soft or hard gelatin shells or capsules for administration, or administered by other means obvious to those skilled in the art.
- Figure 1 is a graph showing the plasma concentration in fasted dogs of the formulation of Example 1 and a reference composition.
- Figure 2 is a graph showing the plasma concentration in fasted dogs of the formulation of Example 2 and a reference composition.
- Figure 3 is a graph showing the plasma concentration in fasted and non-fasted dogs of the formulation of Example 1 and a reference composition.
- the bulk lipid-regulating agent can be prepared by any available method, as for example the compound fenofibrate may be prepared by the procedure disclosed in U.S. Patent No. 4,058,552 or the procedure disclosed in U.S. Patent No. 4,739,101, both herein incorporated by reference.
- propylene glycol fatty acid esters include, but are not limited to, propylene glycol dicaprylate/dicaprate, propylene glycol dicaprate, propylene glycol laurate, and propylene glycol mono- and dicaprylate.
- Preferred propylene glycol fatty acid esters include Miglyol 840TM, a propylene glycol dicaprylate/dicaprate available from Creanova; Captex 100TM, a propylene glycol dicaprate available from Abitec; LauroglycolTM, a propylene glycol laurate available from Miglyol 840TM, a propylene glycol dicaprylate/dicaprate available from Creanova; Captex 100TM, a propylene glycol dicaprate available from Abitec; LauroglycolTM, a propylene glycol laurate available from
- Gattefosse and Capmul PG8TM, a propylene glycol mono- and dicaprylate available from Abitec.
- Suitable emulsifiers include pharmaceutically-acceptable emulsifiers such as, for example, TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate), phospholipids, polyoxyethylene sorbitan fatty acid derivatives, castor oil or hydrogenated castor oil ethoxylates, polyglycerol esters of fatty acids, fatty acid ethoxylates, alcohol ethoxylates, and polyoxyethylene-polyoxypropylene co-polymers and block co-polymers.
- Preferred emulsifiers include castor oil or hydrogenated castor oil ethoxylates.
- a more preferred emulsifier is Cremophor ELTM, a polyoxyl 35 castor oil, available from BASF.
- antioxidants such as, for example, tocopherol, ascorbyl palmitate, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, etc.
- pH stabilizers such as, for example, citric acid, tartaric acid, fumaric acid, acetic acid, glycine, arginine, lysine, potassium hydrogen phosphate, etc.
- thickeners/suspending agents such as, for example, hydrogenated vegetable oils, beeswax, colloidal silicon dioxide, gums, celluloses, silicates, bentonite, etc.
- flavoring agents such as, for example, cherry, lemon, aniseed flavors, etc.
- sweeteners such as, for example, aspartame, saccharin, cyclamates, etc.
- co-solvents such as, for example, ethanol
- the solution comprising the lipid-regulating agent is prepared by dissolving said agent in the propylene glycol fatty acid ester with adequate mixing at or about room temperature. If an emulsifier is used, it is added to the propylene glycol fatty acid ester with mixing prior to addition of said agent.
- the resulting premix liquid comprising said agent may be dosed directly for oral administration, diluted into an appropriate vehicle for oral administration, filled into soft or hard gelatin capsules for oral administration, or delivered by some other means obvious to those skilled in the art.
- the said premix liquid can be used to improve the oral bioavailability, and/or increase the solubility of said agent.
- Capmul PG8 (Abitec) (8.3 gm) was added to a scintillation vial. Cremophor EL (BASF) (1.0 gm) was added to the vial and mixed until uniform. Fenofibrate (Sigma) (0.7 gm) was then added to the vial and mixed until it was completely dissolved. 957 mg. of the premix (containing 67 mg. fenofibrate) was added to each of six soft gelatin capsules using a syringe. The capsules were heat-sealed and stored.
- Cremophor EL BASF
- Fenofibrate Sigma
- Captex 200 (propylene glycol dicaprylate/dicaprate) (Abitec)(9.3 gm) was added to a scintillation vial.
- Fenofibrate (Sigma) (0.7 gm) was added to the Captex 200 and mixed until completely dissolved.
- 957 mg. of the premix (containing 67 mg. fenofibrate) was added to each of six soft gelatin capsules using a syringe. The capsules were heat-sealed and stored.
- Example 4 Capmul PG8 (Abitec) (8.0 gm) is added to a scintillation vial. Cremophor EL (BASF) (1.0 gm) is added to the vial and mixed until uniform. Pravastatin (PravacholTM, Bristol Myers Squibb) (1.0 gm) is then added to the vial and mixed until uniformly dispersed. The premix may be added to soft gelatin capsules in an amount sufficient to deliver the desired dose.
- Example 5 Capmul PG8 (Abitec) (8.0 gm) is added to a scintillation vial. Cremophor EL (BASF) (1.0 gm) is added to the vial and mixed until uniform. Atorvastatin (LipitorTM,
- Parke-Davis/Pfizer (1.0 gm) is then added to the vial and mixed until uniformly dispersed.
- the premix may be added to soft gelatin capsules in an amount sufficient to deliver the desired dose.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21644898A | 1998-12-18 | 1998-12-18 | |
US216448 | 1998-12-18 | ||
PCT/US1999/029696 WO2000037057A2 (en) | 1998-12-18 | 1999-12-15 | Novel formulations comprising lipid-regulating agents |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1140036A2 true EP1140036A2 (en) | 2001-10-10 |
Family
ID=22807109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99967317A Withdrawn EP1140036A2 (en) | 1998-12-18 | 1999-12-15 | Novel formulations comprising lipid-regulating agents |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1140036A2 (en) |
JP (1) | JP2002532539A (en) |
CA (1) | CA2355820A1 (en) |
WO (1) | WO2000037057A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372251B2 (en) * | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6982281B1 (en) | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
DE60219307T2 (en) * | 2001-06-12 | 2008-01-10 | Galephar M/F | ORANGE-TO-USE MEDICAMENT COMPOSITION CONTAINING A STATINE DERIVATIVE |
FR2827770B1 (en) * | 2001-07-27 | 2005-08-19 | Gattefosse Ets Sa | ORAL PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE INGREDIENT LIKELY TO BE SUBSTANTIALLY EFFECT OF FIRST INTESTINAL PASSAGE |
US7642287B2 (en) | 2004-08-06 | 2010-01-05 | Transform Pharmaceuticals, Inc. | Statin pharmaceutical compositions and related methods of treatment |
BRPI0518426A2 (en) * | 2004-12-06 | 2008-11-25 | Reliant Pharmaceuticals Inc | Pharmaceutical compositions comprising fenofibrates and solvent systems |
JP5300477B2 (en) * | 2006-08-01 | 2013-09-25 | 大塚製薬株式会社 | Pharmaceutical composition with improved absorption of pharmacologically active substances |
JP5186159B2 (en) * | 2006-08-31 | 2013-04-17 | あすか製薬株式会社 | Fenofibrate-containing composition |
JP2013047282A (en) * | 2006-08-31 | 2013-03-07 | Aska Pharmaceutical Co Ltd | Fenofibrate-containing composition |
JP5613396B2 (en) * | 2008-10-22 | 2014-10-22 | 参天製薬株式会社 | Pharmaceutical composition for improving intestinal absorption |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
EP2400840A4 (en) * | 2009-02-24 | 2012-08-01 | Madeira Therapeutics | Liquid statin formulations |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
JP7306791B2 (en) | 2015-02-06 | 2023-07-11 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Pharmaceutical composition for combination therapy |
EP3544614A4 (en) | 2016-11-28 | 2020-08-05 | Lipocine Inc. | Oral testosterone undecanoate therapy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE117200T1 (en) * | 1990-12-18 | 1995-02-15 | Merrell Dow Pharma | MEDICINAL PRODUCT CONTAINING PROBUCOL WITH INCREASED BIOAVAILABILITY. |
WO1995014463A1 (en) * | 1993-11-25 | 1995-06-01 | Taisho Pharmaceutical Co., Ltd. | Composition of pharmaceutical preparation improved in peroral absorbability |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US6201009B1 (en) * | 1998-10-30 | 2001-03-13 | Fujirebio Inc. | Absorption-enhancing composition for pantothenic acid derivative |
-
1999
- 1999-12-15 EP EP99967317A patent/EP1140036A2/en not_active Withdrawn
- 1999-12-15 WO PCT/US1999/029696 patent/WO2000037057A2/en not_active Application Discontinuation
- 1999-12-15 CA CA002355820A patent/CA2355820A1/en not_active Abandoned
- 1999-12-15 JP JP2000589168A patent/JP2002532539A/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0037057A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000037057A2 (en) | 2000-06-29 |
CA2355820A1 (en) | 2000-06-29 |
WO2000037057A3 (en) | 2000-11-16 |
JP2002532539A (en) | 2002-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6372251B2 (en) | Formulations comprising lipid-regulating agents | |
EP1162954A1 (en) | Novel formulations comprising lipid-regulating agents | |
US6465011B2 (en) | Formulations comprising lipid-regulating agents | |
EP1140036A2 (en) | Novel formulations comprising lipid-regulating agents | |
US6326360B1 (en) | Bubbling enteric coated preparations | |
CA2367995A1 (en) | Novel formulations comprising lipid-regulating agents | |
US6838091B2 (en) | Formulations comprising lipid-regulating agents | |
US20020102301A1 (en) | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof | |
WO1999029300A1 (en) | Self-emulsifying fenofibrate formulations | |
KR20100038188A (en) | Novel method for producing dry hydrodispersible pharmaceutical forms | |
US6719999B2 (en) | Formulations comprising lipid-regulating agents | |
US6814977B1 (en) | Formulations comprising lipid-regulating agents | |
CN112168781B (en) | Tacrolimus self-microemulsion composition and preparation method thereof | |
US20020040046A1 (en) | Novel formulations comprising lipid-regulating agents | |
US20050192340A1 (en) | Simvastatin formulations and methods of making same | |
US7014864B1 (en) | Formulations comprising lipid-regulating agents | |
EP1183017A1 (en) | Novel formulations comprising lipid-regulating agents | |
EP1643975A2 (en) | Process for preparing formulations of lipid-regulating drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010606 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: REILAND, TOM Inventor name: RAYMOND, DAWN, M. Inventor name: LIPARI, JOHN, M. |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE ES FR GB IT |
|
17Q | First examination report despatched |
Effective date: 20050124 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050606 |